Immunization with a novel recombinant protein (YidR) reduced the risk of clinical mastitis caused by Klebsiella spp. and decreased milk losses and culling risk after Escherichia coli infections

dc.contributor.authorTomazi, T.es_ES
dc.contributor.authorTomazi, A. C. C. Hes_ES
dc.contributor.authorSilva, J. C. C.es_ES
dc.contributor.authorBringhenti, L.es_ES
dc.contributor.authorBravo, M. L. M. C.es_ES
dc.contributor.authorRodrigues, M. X.es_ES
dc.contributor.authorBicalho, R. C.es_ES
dc.date.accessioned2023-03-06T16:55:29Z
dc.date.available2023-03-06T16:55:29Z
dc.date.issued2020-11-30
dc.description.abstractThe primary objective of this study was to evaluate the protective efficacy of a novel recombinant subunit vaccine containing the protein YidR (rYidR) against clinical mastitis (CM) caused by Klebsiella spp. and Escherichia coli. Given that E. coli infection is known to cause metritis, we also evaluated the effect of rYidR vaccination on the incidence of metritis and conception at the first artificial insemination. Retained placenta and abortion incidence, milk production and composition, and serological responses to specific antigens were also evaluated. In total, 3,107 cows were blocked by parity and randomly allocated into 1 of 3 treatment groups: experimental recombinant subunit vaccine containing the YidR protein (rYidR); commercial vaccine composed of Klebsiella pneumoniae siderophore receptors and porin protein (Kleb-SRP; KlebVax, Epitopix, Willmar, MN); and sterile water adjuvanted with aluminum hydroxide (20%; placebo). Vaccinations were performed at the dry-off for cows, and at 223 ± 3 d of pregnancy for pre-fresh heifers. A second administration was given at 21 ± 3 d after the first injection. Vaccination with rYidR significantly reduced the incidence of CM caused by Klebsiella spp. (3.2%) when compared with the placebo (5.1%) group. No difference was observed on risk of Klebsiella CM between Kleb-SRP (5.9%) and placebo groups. Cows in the rYidR group that experienced E. coli CM had a lower risk of death or culling (12.5%) compared with the Kleb-SRP (27.6%) and placebo groups (27.8%). Furthermore, among cows that developed E. coli CM, rYidR-immunized cows produced more milk than did cows in the placebo and Kleb-SRP groups. Regardless of CM occurrence, rYidR-immunized cows tended to have higher milk production up to the eighth month of lactation than cows in the other groups. No significant effect of treatment was observed on the overall incidence of abortion and metritis; however, the risk of retained placenta tended to be lower for the rYidR group (4.7%) compared with the placebo group (6.7%). In addition, primiparous cows in the rYidR group had the highest conception risk at the first artificial insemination (48.3%) compared with the placebo (39.5%) group, and no significant difference was observed when the Kleb-SRP (40.1%) group was compared with the placebo group. Generally, higher antibody serum titers (IgM and IgG) were observed for the immunized groups compared with the placebo. In conclusion, the rYidR vaccine reduced the risk of CM caused by Klebsiella spp. and the mortality or culling of cows with E. coli infections. Other benefits of the novel vaccine include maintenance of milk production after CM caused by E. coli, and higher conception risk at the first service in primiparous cows compared with cows in the placebo and Kleb-SRP groups.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.3168/jds.2020-19173es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.14142/354
dc.language.isoenges_ES
dc.publisherElsevier Inc.es_ES
dc.publisherFass Inces_ES
dc.publisher.countryNLes_ES
dc.relation.ispartofJournal of Dairy Sciencees_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/es_ES
dc.sourceJournal of Dairy Science Vol. 104 No. 4, 2021es_ES
dc.subjectClinical mastitises_ES
dc.subjectRecombinant vaccinees_ES
dc.subjectKlebsiella spp.es_ES
dc.subjectColiformses_ES
dc.subject.ocdehttp://purl.org/pe-repo/ocde/ford#4.05.00es_ES
dc.titleImmunization with a novel recombinant protein (YidR) reduced the risk of clinical mastitis caused by Klebsiella spp. and decreased milk losses and culling risk after Escherichia coli infectionses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersiones_ES

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S0022030221001491-main.pdf
Size:
2.85 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: